Urinary water clearance after infusion of conivaptan, a combined vasopressin V1a and V2 receptor antagonist, in patients with NYHA class III/IV heart failure

被引：0
|
作者：
Painchaud, CA
Ghazzi, MM
Selaru, P
Bichet, DG
Chartier, KK
Udelson, JE
机构：
[1] Parke Davis Pharmaceut Res, Ann Arbor, MI USA
[2] Hosp Sacre Coeur Montreal, Montreal, PQ, Canada
[3] New England Med Ctr, Boston, MA 02111 USA
来源：
CIRCULATION | 2000年 / 102卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2603
引用
收藏
页码：535 / 535
页数：1
相关论文
共 50 条
  • [41] Conivaptan, a Selective Arginine Vasopressin V1a and V2 Receptor Antagonist Attenuates Global Cerebral Edema Following Experimental Cardiac Arrest via Perivascular Pool of Aquaporin-4
    Nakayama, Shin
    Amiry-Moghaddam, Mahmood
    Ottersen, Ole Petter
    Bhardwaj, Anish
    NEUROCRITICAL CARE, 2016, 24 (02) : 273 - 282
  • [42] Pharmacokinetics of Conivaptan Hydrochloride, a Vasopressin V1A/V2-Receptor Antagonist, in Patients With Euvolemic or Hypervolemic Hyponatremia and With or Without Congestive Heart Failure From a Prospective, 4-Day Open-Label Study
    Mao, Zhongping Lily
    Stalker, Dennis
    Keirns, James
    CLINICAL THERAPEUTICS, 2009, 31 (07) : 1542 - 1550
  • [43] Preclinical evaluation of a novel dual acting V1a/V2 vasopressin receptor antagonist by using a noninvasive cardiac output monitor
    Mondritzki, T. Thomas
    Boehme, P.
    Sandner, P.
    Dinh, W.
    Hueser, J.
    Truebel, H.
    Kolkhof, P.
    EUROPEAN JOURNAL OF HEART FAILURE, 2018, 20 : 335 - 335
  • [44] Temporal trends of a vasopressin V2 receptor antagonist in heart failure using a nationwide database in Japan
    Kuragaichi, Takashi
    Sato, Yukihito
    ESC HEART FAILURE, 2021, 8 (01): : 527 - 538
  • [45] A novel oral vasopressin V2 receptor antagonist for the treatment of acute decompensated heart failure and hyponatremia
    Jennings, Douglas L.
    Kalus, James S.
    FORMULARY, 2008, 43 (07) : 236 - +
  • [46] Effect of the V1a/V2-AVP receptor antagonist, Conivaptan, on renal water metabolism and systemic hemodynamics in rats with cirrhosis and ascites
    Fernández-Varol, G
    Ros, J
    Cejudo-Martín, P
    Cano, C
    Arroy, V
    Rivera, F
    Rodés, J
    Jiménez, W
    JOURNAL OF HEPATOLOGY, 2003, 38 (06) : 755 - 761
  • [47] Effect of long-term treatment with selective vasopressin V1 and V2 receptor antagonist on the development of heart failure in rats
    Nishikimi, T
    Kawano, Y
    Saito, Y
    Matsuoka, H
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1996, 27 (02) : 275 - 282
  • [48] Chronic vasopressin V2-but not V1a receptor blockade prevents heart failure in rats with myocardial infarction.
    Schoemaker, RG
    Van Veghel, R
    Lankhuizen, IM
    CIRCULATION, 2000, 102 (18) : 75 - 75
  • [49] Evaluating the efficacy and safety of the novel vasopressin V1A- and V2-receptor antagonist conivaptan for the treatment of acute decompensated chronic heart failure:: Study protocol
    Goldsmith, SR
    Bisaha, JG
    Smith, N
    JOURNAL OF CARDIAC FAILURE, 2004, 10 (04) : S85 - S85
  • [50] Next-generation spirobenzazepines:: Identification of RWJ-676070 as a balanced vasopressin V1a/V2 receptor antagonist for human clinical studies
    Xiang, Min Amy
    Rybczynski, Philip J.
    Patel, Mona
    Chen, Robert H.
    McComsey, David F.
    Zhang, Han-Cheng
    Gunnet, Joseph W.
    Look, Richard
    Wang, Yuanping
    Minor, Lisa K.
    Zhong, H. Marlon
    Villani, Frank J.
    Demarest, Keith T.
    Damiano, Bruce P.
    Maryanoff, Bruce E.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (23) : 6623 - 6628
12345